EUVIMEDEUVIMED entdecken
Fallbericht

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance

Michiel A Damhof iD, Lisanne N van Merendonk iD, Marco B Polee, Marjan Bouma, Eric N van Roon, Alwin D R Huitema, Annemieke Cats, Bart A W Jacobs

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70476 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Michiel A Damhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, Frisius Medical Center, Leeuwarden, The Netherlands. Hauptthemen laut MEDLINE: Capecitabine, Dihydropyrimidine Dehydrogenase Deficiency, Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complete dihydropyrimidine dehydrogenase (DPD) deficiency due to homozygous DPYD*2A is a contraindication for fluoropyrimidines because of the extreme risk of life‐threatening toxicity. We report a 36‐year‐old male with metastatic rectal adenocarcinoma and complete DPD deficiency who received ultra‐low‐dose capecitabine in combination with oxaliplatin and cetuximab. Initial dosing of capecitabine 150 mg on Days 1, 6 and 16 of a 21‐day cycle (0.76% of the BSA‐based standard regimen) caused Grade 3 mucositis, but further dose reduction to capecitabine 150 mg on Days 1 and 8 of a 21‐day cycle (0.50%) improved tolerability. Pharmacokinetic analyses revealed markedly prolonged 5‐fluorouracil exposure with undetectable fluoro‐β‐alanine (FBAL), consistent with complete DPD deficiency. Despite the minimal dosing, a near‐complete metabolic response was achieved after four cycles, enabling surgical resection of residual disease. This case illustrates that carefully individualized ultra‐low‐dose capecitabine, guided by pharmacokinetics and toxicity monitoring, can provide meaningful clinical benefit in patients with complete DPD deficiency. These findings highlight the therapeutic potential of a precision dosing approach in this rare but clinically challenging setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineDihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticAdenocarcinomaRectal NeoplasmsHumansMaleAdultHomozygoteAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeFluorouracil

Stichwörter der Autor:innen

DPD deficiencyDPYD*2Acapecitabinecase reportfluoropyrimidine toxicitypharmacokinetics

Substanzen

CapecitabineDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticFluorouracil

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, Frisius Medical Center, Leeuwarden, The Netherlands.
  • Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Frisius Medical Center, Leeuwarden, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Gastroenterology and Hepatology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Michiel A Damhof, Lisanne N van Merendonk

Zitieren

APA

Damhof, M. A., van Merendonk, L. N., Polee, M. B., Bouma, M., van Roon, E. N., Huitema, A. D. R., Cats, A., & Jacobs, B. A. W. (2026). Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70476

Vancouver

Damhof MA, van Merendonk LN, Polee MB, Bouma M, van Roon EN, Huitema ADR, et al. Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70476

BibTeX
@article{Damhof2026,
  author = {Damhof, Michiel A and van Merendonk, Lisanne N and Polee, Marco B and Bouma, Marjan and van Roon, Eric N and Huitema, Alwin D R and Cats, Annemieke and Jacobs, Bart A W},
  title = {Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70476}
}
Kostenlos starten →